BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement

Rhea-AI Summary

BioNxt Solutions (OTC:BNXTF) has successfully closed the final tranche of its oversubscribed convertible debenture unit private placement, raising $241,200 in gross proceeds. Combined with the previous tranche, the total offering reached $1,250,400.

The debenture units, priced at $0.60 each, consist of 8.0% unsecured convertible debentures and one common share purchase warrant. The warrants are exercisable at $0.75 per share for two years. The debentures feature an 8.0% annual interest rate and are convertible into common shares at $0.60 per share. The company plans to use the proceeds for product development, commercialization, IP filings, and working capital.

Positive

• Successfully raised total gross proceeds of $1,250,400 through oversubscribed offering
• Flexible financing structure with 8.0% interest rate and conversion options
• Warrants provide additional funding potential at $0.75 per share

Negative

• Potential dilution for existing shareholders upon conversion of debentures and exercise of warrants
• Additional debt burden with 8.0% annual interest rate

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, BC / ACCESS Newswire / August 8, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:BNXTF)(FSE:BXT), is pleased to announce today that it has closed the final tranche of its previously announced non‐brokered private placement (the "Offering") of convertible debenture units (the "Debenture Units") at a price of $0.60 per Debenture Unit, for gross proceeds of $241,200. The $241,200 represents the principal amount outstanding pursuant to the Debentures (as defined herein); the Company also issued 402,000 Warrants (as defined herein) pursuant to the closing of the final tranche of the Offering.

Over the two tranches of the Offering, the Company raised aggregate gross proceeds of $1,250,400, representing the aggregate principal amount outstanding pursuant to the Debentures, and issued a total of 2,084,000 Warrants.

Each Debenture Unit consisted of: (i) $0.60 principal amount of 8.0% unsecured convertible debentures (the "Debentures") and (ii) one common share purchase warrant (each a "Warrant"). Each Warrant entitles the holder to acquire one common share in the capital of the Company (a "Common Share") at a price of $0.75 per Common Share for a period of two years following the date of issuance. The Debentures bear interest from their issue date at 8.0% per annum on an accrual basis, calculated and payable on an annual basis, up to and including the date which is two years following the date of issuance (the "Maturity Date"). The principal amount of the Debentures is convertible, at the option of the holder, into Common Shares at any time prior to the Maturity Date, at a conversion price of $0.60 per Common Share (the "Conversion Price"). At the election of the Company, the interest payable on the principal amount of the Debentures may be settled by a cash payment or through the issuance of Common Shares at the Conversion Price.

The Company intends to use the net proceeds from the Offering for product development and commercialization, intellectual property filings, and general working capital.

In connection with the closing of the final tranche of the Offering, the Company paid an aggregate cash finder fee of $19,296 and issued an aggregate of 32,160 finder's warrants to Canaccord Genuity Corp. (the "Finder Warrants"). Each Finder Warrant will entitle the holder to purchase one Common Share (a "Finder Share") at an exercise price of $0.60 per Finder Share for a period of two years from the date of issuance of the Finder Warrants.

The securities of the Company issued in connection with the final tranche of the Offering, and any Common Shares issuable upon conversion or exercise thereof, are subject to a statutory hold period until December 9, 2025, in accordance with applicable Canadian securities laws.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience innovator focused on next‐generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin‐Film), Transdermal (Skin Patch), and Oral (Enteric‐Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient‐centric solutions that enhance treatment outcomes worldwide.

BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.

Investor Relations & Media Contact

Hugh Rogers, Co‐Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt‐solutions
Instagram: https://www.instagram.com/bionxt

THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF ANY OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL. THE DEBENTURES AND THE SHARES WHICH MAY BE ISSUED ON EXERCISE THEREOF HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT") AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS.

Cautionary Statement Regarding "Forward‐Looking" Information

This news release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking information in this news release includes the projected use of proceeds from the Offering. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE: BioNxt Solutions Inc.

View the original press release on ACCESS Newswire

FAQ

How much did BioNxt Solutions (BNXTF) raise in their latest convertible debenture offering?

BioNxt raised $241,200 in the final tranche, bringing the total offering to $1,250,400 across both tranches.

What are the key terms of BioNxt's convertible debentures?

The debentures have an 8.0% annual interest rate, are convertible at $0.60 per share, and include warrants exercisable at $0.75 per share for two years.

When do BioNxt's (BNXTF) new convertible debentures mature?

The debentures mature two years following their date of issuance.

How will BioNxt Solutions use the proceeds from the convertible debenture offering?

The proceeds will be used for product development and commercialization, intellectual property filings, and general working capital.

What is the statutory hold period for BioNxt's new securities?

The securities are subject to a statutory hold period until December 9, 2025, in accordance with Canadian securities laws.